Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer. [artículo]
Por: Blasco Benito, Sandra [Instituto de Investigación imas12]
| Andradas, Clara [Instituto de Investigación imas12]
| Sánchez, Cristina [Instituto de Investigación imas12]
.
Colaborador(es): Instituto de Investigación imas12
.
Tipo de material: ![materialTypeLabel](/opac-tmpl/lib/famfamfam/AR.png)
Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
---|---|---|---|---|
![]() |
PC17351 (Navegar estantería) | Disponible |
Formato Vancouver:
Morales P, Blasco Benito S, Andradas C, Gómez Cañas M, Flores JM, Goya P et al. Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer. J Med Chem. 2015 Mar 12;58(5):2256-64.
PMID: 25671648
Contiene 50 referencias
Triple-negative breast cancer (TNBC) represents a subtype of breast cancer characterized by high aggressiveness. There is no current targeted therapy for these patients whose prognosis, as a group, is very poor. Here, we report the synthesis and evaluation of a potent antitumor agent in vivo for this type of breast cancer designed as a combination of quinone/cannabinoid pharmacophores. This new compound (10) has been selected from a series of chromenopyrazolediones with full selectivity for the nonpsychotropic CB2 cannabinoid receptor and with efficacy in inducing death of human TNBC cell lines. The dual concept quinone/cannabinoid was supported by the fact that compound 10 exerts antitumor effect by inducing cell apoptosis through activation of CB2 receptors and through oxidative stress. Notably, it did not show either cytotoxicity on noncancerous human mammary epithelial cells nor toxic effects in vivo, suggesting that it may be a new therapeutic tool for the management of TNBC.
No hay comentarios para este ejemplar.